NCT04782388View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

April 26, 2021

Study Completion Date

April 26, 2021

Conditions
Healthy Study Participants
Interventions
DRUG

Alprazolam

Study participants will receive Staccato alprazolam at prespecified time-point.

OTHER

Placebo

Study participants will receive Staccato placebo at prespecified time-point.

Trial Locations (1)

92801

Up0101 101, Anaheim

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04782388 - Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants | Biotech Hunter | Biotech Hunter